Anti-VEGF Treatment Strategies for Wet AMD Report Summary

Anti-VEGF Treatment Strategies for Wet AMD Report Summary

Author or authors of report : Jaclyn L. Kovach, Stephen G. Schwartz, Harry W. Flynn, Jr, Ingrid U. Scott,
Date of report : 2012-02-28

Major Points:

  1. Introduction to AMD: Age-related macular degeneration is a complex condition involving interactions between various biological factors that can lead to choroidal neovascularization (CNV). VEGF plays a crucial role in this process.
  2. Animal Studies: Studies in monkeys have shown that anti-VEGF therapies can prevent the development of CNV and reduce leakage from preexisting CNV.
  3. Pegaptanib: This is a selective inhibitor of VEGF. Clinical trials have shown that intravitreal administration of pegaptanib reduced the chance of moderate and severe vision loss in patients with neovascular AMD.
  4. Bevacizumab: Initially approved for the treatment of metastatic colon cancer, bevacizumab has been found to be effective in treating AMD. It is well-tolerated and associated with an average of a 14-letter gain in best-corrected visual acuity (BCVA).
  5. Ranibizumab: This antibody fragment has been engineered to have 100 times the binding affinity of bevacizumab. Clinical trials have shown significant gains in visual acuity compared to control groups.
  6. Comparison of Treatments: The report suggests that the efficacy of intravitreal bevacizumab and ranibizumab is comparable for most patients, with the primary difference being the cost.
  7. Clinical Trials: Various trials like the MARINA and ANCHOR trials have demonstrated the efficacy and safety of ranibizumab in treating AMD. These trials have shown significant gains in visual acuity and low rates of adverse events.

Findings:

  • Anti-VEGF therapies have become the standard treatment for neovascular AMD.
  • Individualized treatment regimens have evolved from a monthly dosing schedule.
  • Both bevacizumab and ranibizumab are effective, but ranibizumab is considerably more expensive.
  • Clinical trials support the efficacy and safety of these treatments.